|
Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome Clinical research trials and Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome. Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome clinical trial. Human subjects often obtain the finest healthcare possible for their Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome  Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome
Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome
For Condition: Leukemia
Status: No longer recruiting
Sponsor(s): Barbara Ann Karmanos Cancer Institute ,
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy and kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of bone marrow transplantation following combination chemotherapy in treating patients with acute myeloid leukemia or myelodysplastic syndrome.
Details: OBJECTIVES: I. Evaluate overall and leukemia-free survival of patients with acute nonlymphocytic leukemia and myelodysplastic syndromes treated with busulfan/cyclophosphamide (low-risk patients) or cytarabine/busulfan/cyclophosphamide (high-risk patients) followed by allogeneic or syngeneic bone marrow transplant. II. Compare the therapeutic effects of these cytoreduction regimens with those reported in the literature for similar patients who undergo syngeneic or allogeneic marrow transplantation following cytoreduction that includes total-body irradiation. III. Evaluate early and late toxicities produced by these chemotherapy regimens. PROTOCOL OUTLINE: Low-risk patients (those in first CR who achieved CR with 1 cycle of chemotherapy) are treated on Regimen A; high-risk patients (those in second or subsequent remission who required more than 1 cycle of chemotherapy to achieve first CR, those with MDS, or those with current or prior CNS involvement) are treated on Regimens B and C. The following acronyms are used: ARA-C Cytarabine, NSC-63878 BMT Bone Marrow Transplant BU Busulfan, NSC-750 CF Leucovorin calcium, NSC-3590 CTX Cyclophosphamide, NSC-26271 CYSP Cyclosporine, NSC-290193 GVHD Graft-Versus-Host Disease MTX Methotrexate, NSC-740 Regimen A: 2-Drug Cytoreductive Chemotherapy followed by Bone Marrow Transplantation with, as indicated, GVHD Prophylaxis. BU/CTX; followed by allogeneic or syngeneic BMT; with, for allogeneic BMT, CYSP/MTX Regimen B: 3-Drug Cytoreductive Chemotherapy followed by Bone Marrow Transplantation with, as indicated, GVHD Prophylaxis. BU/CTX/ARA-C; followed by allogeneic or syngeneic BMT; with, for allogeneic BMT, CYSP/MTX. Regimen C: CNS Prophylaxis/Therapy. IT MTX/CF (or IT ARA-C if MTX is contraindicated). PROJECTED ACCRUAL: 40 evaluable patients will be entered over 2.7 years.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: /60 Years
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - The following hematologic malignancies are eligible: Acute nonlymphocytic leukemia in one of the following categories: In complete remission In early relapse; Newly diagnosed FAB types; M6 and M7 - Myelodysplastic syndromes including: Refractory anemia with excessive blasts; Refractory anemia with excessive blasts in transformation; Chronic myelomonocytic leukemia - Secondary acute myeloid leukemia - Transplantation priority given in decreasing order of: First remission; Second remission; Third remission; Early relapse, with priority further reduced for: Refractory response to platelet transfusion; Severe infection within 6 weeks prior to referral; History of major organ pathology or insult (hepatitis, renal damage, pulmonary disease, cystitis, etc.) - CNS disease allowed but priority status for transplantation lowered - Sibling or matched related/unrelated donor required; Donor priority as follows: Monozygotic twin; Genotypical or phenotypical HLA-A, -B, -C, and -D match; Match at any 2 loci (A, B, Dr) on the other haplotype - ABO-compatible donor preferred; Marrow processed to eliminate mismatched erythrocytes if ABO incompatible - In case of multiple donors, priority is: ABO compatibility; Age over 18; Same sex - No physiologic, psychologic, or medical contraindication to donation procedure - No increased anesthetic risk due to pre-existing illness - No HIV infection --Prior/Concurrent Therapy-- - See Disease Characteristics --Patient Characteristics-- - Age: 6 months to 60 years - Performance status: Not specified - Life expectancy: No severe limits on life expectancy due to diseases other than leukemia; No preterminal or moribund patients - Hematopoietic: Not specified - Hepatic: Bilirubin no greater than 2.0 mg/dl; Transaminases no greater than 3 x normal; No severe hepatic disease - Renal: Creatinine no greater than 1.5 mg/dl OR Creatinine clearance at least 60 ml/min; No severe renal disease; No history of severe cystitis with CTX - Cardiovascular: LVEF at least 50%; No symptomatic cardiac disease - Pulmonary: FEV1 and FVC at last 75% of normal; No severe pulmonary disease - Other: No evidence of HIV infection; No severe personality disorder or severe mental illness; No condition (such as substance abuse) that would markedly increase the morbidity and mortality of transplantation - Criteria of hepatic, renal, cardiac, and pulmonary function and mental illness are used only for initial screening of potential candidates; patients who do not meet these criteria may still be eligible at the discretion of the transplant team
Total Enrollment:
Location and Contact Information:
Overall Study Official:
JaredKlein, Study Chair, Barbara Ann Karmanos Cancer Institute
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201
United States
Additional Information:
Study ID Numbers: CDR0000063305; WSU-D-696-87,NCI-V93-0345
Study Start Date: August 1987
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002547
Other Leukemia Studies:
1. Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors
2. Clinical, Laboratory and Epidemiologic Pilot Studies of Individuals at High Risk for Viral-Associated Cancers
3. High-Dose Cytarabine Plus Deoxycytidine in Treating Patients With Acute Myelogenous Leukemia or Other Hematologic Malignancies
4. Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated with the Epstein Barr Virus
5. Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis
Related Studies:
Other Leukemia Clinical Trials
Other Michigan Clinical Trials
Other Detroit Clinical Trials
Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome
|
|
|
|
|
|
|
|
